There is more to Boston Scientific than the troubled heart stent and defibrillator businesses for which it is best known -- enough, in fact, that the company predicts it could raise at least $1 billion by spinning off a portion to the public.
Boston Scientific, based in Natick, Mass., said yesterday that it was considering a public stock offering for 18 percent to 25 percent of those other businesses, which are grouped under its Endosurgery division.
